NCT05732831 2026-04-21Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid TumorsTango Therapeutics, Inc.Phase 1/2 Recruiting225 enrolled
NCT06239272 2026-04-21NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)St. Jude Children's Research HospitalPhase 1/2 Recruiting139 enrolled
NCT05275478 2026-04-15Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid TumorsTango Therapeutics, Inc.Phase 1/2 Terminated110 enrolled